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ABSTRACT
Objective: Retinopathy is an established
microvascular complication of type 2 diabetes mellitus
(T2DM), but its independent relationship with
macrovascular and other microvascular complications
is less well defined across the spectrum of kidney
disease in T2DM. We examined the prognostic value of
retinopathy in assessing the risk of developing end-
stage renal disease (ESRD), cardiovascular morbidity
or death among patients in the Trial to Reduce
cardiovascular Events with Aranesp Therapy (TREAT).
Design: TREAT enrolled 4038 patients with T2DM,
chronic kidney disease (CKD) and moderate anemia.
Patients were grouped by baseline history of
retinopathy. Proportional hazards regression models
were utilized to assess the association between
retinopathy and subsequent ESRD, cardiovascular
morbidity or death over an average of 2.4 years.
Results: Although younger, the 1895 (47%) patients
with retinopathy had longer duration of diabetes, lower
estimated glomerular filtration rate, more proteinuria,
and more microvascular complications. In univariate
analysis, retinopathy was associated with a higher rate
of ESRD, but not with cardiovascular events or
mortality. After adjustment, retinopathy was no longer
statistically significant for the prediction of ESRD or
any clinical endpoint.
Conclusions: In a large cohort of patients with T2DM,
CKD, and anemia, retinopathy was common but not
independently associated with a higher risk of renal or
cardiovascular morbidity or death.
Trial registration number: NCT00093015
INTRODUCTION
Retinopathy, nephropathy, and neuropathy
are traditionally considered microvascular
complications of diabetes mellitus, while cor-
onary artery disease, stroke, and peripheral
arterial disease are grouped as macrovascular
complications. Among the microvascular
complications of diabetes, chronic kidney
disease (CKD) is a well-established risk factor
for the development of cardiovascular (CV)
disease.1 Despite the devastating effects of
diabetic retinopathy on progressive visual
impairment, blindness, and quality of life,
the predictive value of this ophthalmological
complication for development of CV disease,
worsening renal function, and death is not
fully deﬁned across the spectrum of kidney
disease in diabetes.
Several studies have shown in individuals
with diabetes that the presence and severity
of retinopathy is associated with an increased
risk of CV disease, but it is not clear if this is
independent of the classic hallmarks of dia-
betic nephropathy, proteinuria, and reduced
estimated glomerular ﬁltration rate
(eGFR).2–7 Retinal microvascular abnormal-
ities have also been associated with worsen-
ing renal function in patients with type 2
diabetes,8 9 but studies investigating the rela-
tionship between retinopathy and the devel-
opment of end-stage renal disease (ESRD) in
patients with type 2 diabetes who already
have moderate to severe CKD are lacking.
We examined the prognostic value of retin-
opathy in assessing the risk of developing
ESRD, CV morbidity, and mortality in
patients with type 2 diabetes mellitus, moder-
ate to severely impaired renal function, and
anemia in the Trial to Reduce cardiovascular
Events with Aranesp Therapy (TREAT).
Key messages
▪ In a large cohort of patients with T2DM, CKD,
and anemia, retinopathy was common, affecting
47% of patients enrolled in TREAT.
▪ Patients with retinopathy had a longer duration
of diabetes, lower eGFR, more proteinuria, and
more microvascular complications than patients
without retinopathy.
▪ In univariate analysis, retinopathy was associated
with a higher rate of ESRD, but not with cardio-
vascular events or mortality. After adjustment,
retinopathy was no longer statistically significant
for the prediction any clinical endpoint.
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METHODS
Patients
TREAT (ClinicalTrials.gov registration number
NCT00093015) was a prospective, randomized, double-
blind, placebo-controlled trial of darbepoetin alfa for the
treatment of anemia in 4038 patients with type 2 diabetes
mellitus, impaired renal function (eGFR 20–60 mL/min/
1.73 m2 by MDRD), hemoglobin ≤11.0 g/dL, and transfer-
rin saturation ≥15%. Exclusion criteria included uncon-
trolled hypertension, previous kidney transplantation or
scheduled receipt of a kidney transplant from a living
related donor, current use of intravenous antibiotics,
chemotherapy or radiation therapy, cancer (except basal-
cell or squamous-cell carcinoma of the skin), HIV infec-
tion, active bleeding, or pregnancy. In addition, patients
who had a CV event, major surgery, grand mal seizure, or
had received an erythropoetic stimulating agent within
12 weeks prior to randomization were also ineligible. The
primary endpoints for the study were time to the compos-
ite outcome of death or CV event (non-fatal myocardial
infarction, congestive heart failure, stroke, or hospitaliza-
tion for myocardial ischemia) and time to the composite
outcome of death or ESRD. All endpoints, including
ESRD, were adjudicated by a clinical endpoints committee
masked to treatment assignment. ESRD was deﬁned as the
initiation of dialysis (sustained for at least 30 days), initi-
ation of dialysis with death within 30 days, a physician’s rec-
ommendation to initiate dialysis with documented subject
refusal, or renal transplant. The detailed study design,
entry criteria and main results have been previously
described.10 11
For this analysis, all 4038 TREAT participants were
included, and all gave written informed consent for par-
ticipation in the primary trial. At screening, investigators
were asked to answer checkbox questions about retinop-
athy in each eye—whether or not there was retinopathy
and, if so, to check all that applied of: background/pre-
proliferative, macular edema, proliferative or laser treat-
ment. Questions regarding the baseline presence of a
history of diabetic neuropathy, erectile dysfunction, foot
ulcer, and amputation were also part of the screening
evaluation performed by the site investigator.
Measurements of serum BUN (blood urea nitrogen),
creatinine, albumin, and potassium were obtained at
baseline and eGFR was determined using the four-
variable MDRD equation.12 Baseline proteinuria was
assessed by spot urine protein/creatinine ratio measure-
ments at baseline. All samples were analyzed by a central
laboratory. In a subgroup of the ﬁrst 1000 randomized
patients, troponin T (TnT) and N-terminal pro-B-type
natriuretic peptide (NT-proBNP) were measured in a
single batch from baseline serum samples.13 14
Statistical analysis
Baseline characteristics were stratiﬁed by a history of ret-
inopathy and laser therapy. Categorical variables were
compared using χ2 tests and continuous variables were
compared using the Wilcoxon rank-sum test. All tests
were two sided, and a p value <0.05 was considered statis-
tically signiﬁcant. At baseline, the univariate association
between any degree of retinopathy or laser treated retin-
opathy and the CV composite endpoint, death, CV
death, myocardial infarction, stroke, congestive heart
failure, ESRD, as well as the composite of all-cause mor-
tality or ESRD was analyzed in Cox proportional hazards
regression models. The assumption of proportionality
for the Cox analysis was tested and the criteria were met.
Multivariable proportional hazards models were con-
structed for ESRD and the renal and CV composite out-
comes. The initial model was adjusted for the baseline
demographics of age, sex and race. The ﬁrst model was
nested in the second which also adjusted for
proteinuria. The third model additionally adjusted for
baseline eGFR. Model 4 adjusted for systolic blood pres-
sure and a history of hypertension. Model 5 adjusted for
glycemic control, known duration of diabetes, and
insulin use and the ﬁnal model included all prior covari-
ates in addition to all baseline characteristics that were
signiﬁcantly different between patients with and without
retinopathy. All variables collected in the baseline case
report form were eligible for use in this analysis unless
they were missing for >150 patients. After the exclusion
of missing data, 3894 patients were available for this ana-
lysis. Stata/SE V.12.1 (StataCorp, College Station, Texas,
USA) was used for all analysis.
RESULTS
Baseline analyses
Of the 4038 TREAT patients analyzed, 1895 (47%) had
a baseline history of retinopathy. The majority of them
(n=1174) also had a history of laser photocoagulation
therapy. Table 1 shows the clinical characteristics of the
two groups.
Compared to those with no retinopathy, despite being
younger, individuals with a history of retinopathy had a
longer known duration of diabetes, higher glycosylated
hemoglobin (HbA1c) levels, and were more likely to be
using insulin. Those with retinopathy were also more
likely to be non-smokers, and have slightly higher blood
pressure (138/72 mm Hg vs 134/70 mm Hg, p<0.001).
The median eGFR in patients with retinopathy was
32.4 mL/min/1.73 m2 compared to 34.7 mL/min/
1.73 m2 in patients without retinopathy (p<0.001). The
median ratio of total protein (in mg/dL) to creatinine
(in mg/dL) in urine was higher in patients with retinop-
athy compared to those without retinopathy (0.8 (0.2–
2.7) vs 0.2 (0.1–1.1)); 44.9% of patients with retinopathy
had >1 g total protein/gram creatinine in their urine
versus 25.5% of those without retinopathy (p<0.001).
Patients with retinopathy also had slightly higher total
cholesterol (171 mg/dL vs 168 mg/dL, p<0.01) and low
density lipoprotein (87 mg/dL vs 83 mg/dL, p<0.001),
but lower C reactive protein (CRP) levels (56.3% had
CRP≤3 mg/L vs 44.8%; p<0.001). The baseline preva-
lence of CV disease overall was similar in the two
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Table 1 Baseline characteristics
No retinopathy Retinopathy
N=2143 (53%) N=1895 (47%) p Value
Age (year) 71 (63–77) 65 (58–72) <0.001
Female sex (%) 57.4 57.2 0.90
Race <0.001
White (%) 65.3 61.7
Black (%) 21.3 18.9
Other (%) 13.4 19.4
BMI (kg/m2) 30.2 (26.2–35.3) 30.4 (26.3–35.0) 0.59
Duration of DM (year) 11.6 (5.9–19.4) 18.4 (11.9–25.1) <0.001
Glycated hemoglobin (%) 6.7 (6.1–7.7) 7.3 (6.5–8.3) <0.001
Glycated hemoglobin (mmol/mol) 50 (43–61) 56 (48–67) <0.001
Current smoking (%) 5.8 4.2 <0.001
History of cardiovascular disease (%) 66.4 64.4 0.19
Coronary artery disease (%) 46.2 42.3 0.02
Heart failure (%) 32.6 34.3 0.26
Myocardial infarction (%) 19.0 17.6 0.26
Stroke (%) 11.3 10.8 0.63
Peripheral arterial disease (%) 19.4 22.8 0.01
Hypertension (%) 91.4 93.6 0.01
Atrial fibrillation (%) 12.9 7.8 <0.001
Blood pressure (mm Hg)
Systolic 134 (120–145) 138 (125–150) <0.001
Diastolic 70 (64–80) 72 (66–80) <0.001
Heart rate (bpm) 72 (64–80) 72 (64–80) 0.06
eGFR (mL/min/1.73 m2) 35 (27–43) 32 (25–41) <0.001
Ratio of total protein (in mg/dL) to Cr (in mg/dL) in urine
Median (IQR) 0.2 (0.1–1.1) 0.8 (0.2–2.7) <0.001
≥1 g/g (%) 25.5 44.9 <0.001
Serum albumin (g/dL) 4.0 (3.8–4.3) 4.0 (3.7–4.2) <0.001
Cholesterol (mg/dL)
Total 168 (141–197) 171 (143–207) 0.003
LDL 83 (63–107) 87 (64–115) 0.001
HDL 45 (38–55) 45 (39–55) 0.17
Triglycerides 154 (109–233) 155 (111–228) 0.93
CRP <0.001
≤3.0 (%) 48.8 56.3
>6.6 (%) 28.5 21.6
Medications (%)
Insulin 36.2 64.1 <0.001
Oral hypoglycemic agent 63.6 49.1 <0.001
Thiazolidinedione 27.8 20.5 <0.001
Sulfonamide 39.8 30.5 <0.001
Biguanide 19.5 14.6 <0.001
ACE or ARB 77.9 82.0 0.001
ACE and ARB 9.2 11.0 >0.05
β-blocker 50.5 47.9 0.10
Aldosterone antagonist 5.9 4.3 0.02
Statin 58.1 59.1 0.50
Any lipid lowering agent 64.9 63.5 0.36
Aspirin 41.2 43.9 0.08
Dual antiplatelet therapy 47.6 49.0 0.38
Vitamin K antagonist 8.6 4.9 <0.001
Iron
Oral 42.2 42.4 0.93
Intravenous 1.3 1.8 0.21
Prior use of erythropoietic agent 8.7 10.5 0.06
Darbepoetin 48.7 51.1 0.12
Values are expressed as medians (IQRs) or as percentages.
ARB, angiotensin receptor blocker; BMI, body mass index; Cr, creatinine; CRP, C reactive protein; DM, diabetes mellitus; eGFR, estimated
glomerular filtration rate; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
BMJ Open Diabetes Research and Care 2014;2:e000011. doi:10.1136/bmjdrc-2013-000011 3
Cardiovascular and metabolic risk
group.bmj.com on April 30, 2017 - Published by http://drc.bmj.com/Downloaded from 
groups, although atrial ﬁbrillation was less prevalent in
patients with retinopathy (table 1). Patients with retinop-
athy were also more likely to be taking an ACE inhibitor
or angiotensin receptor blocker (ARB), but less likely to
be on an aldosterone antagonist; there was no signiﬁcant
difference between groups in the use of combination
therapy with an ACE and ARB.
Among patients with retinopathy, those with a history
of laser photocoagulation, as a marker of more severe
eye disease, had an even longer known duration of dia-
betes (20 years, IQR (13.3–25.5) vs 16.6 (10.5–24.1)),
higher median HbA1c (7.4%, IQR (6.6–8.5) vs 7.1%
(6.4–8.2)) and more insulin use (67.3% vs 58.8%; all p
values <0.01 for the comparison of retinopathy with and
without laser therapy, and <0.001 for the trend from no
retinopathy, to retinopathy without laser therapy, to ret-
inopathy with laser therapy).
Complications of diabetes
All patients enrolled in TREAT had diabetes mellitus,
renal dysfunction, and anemia; however, patients with ret-
inopathy had more microvascular complications of dia-
betes (ﬁgure 1). Patients with retinopathy also had higher
rates of foot ulcers and amputation, all of which occurred
at an earlier age compared to those without retinopathy.
Among patients with retinopathy, those with a history of
laser photocoagulation were signiﬁcantly more likely to
report diabetic neuropathy at baseline than those with less
severe retinopathy (64.4% vs 58.6%, p<0.05).
Biomarkers
Of the patients with retinopathy, 51.1% had a detectible
level of TnT (≥0.01 ng/mL), compared to 38.2% of
those without retinopathy (p<0.001). There was no sig-
niﬁcant difference in detectible TnT levels among
patients with retinopathy when further stratiﬁed by a
history of laser therapy. Median NT-proBNP levels were
similar among the three groups (595.5 pg/mL for
patients with no history of retinopathy, 604.2 pg/mL for
patients with a history of retinopathy but no laser therapy,
and 616.6 pg/mL for patients with a history of retinop-
athy and laser photocoagulation therapy (p=0.83)).
Retinopathy and outcomes
During the study period, 1234 patients developed the
primary composite endpoint of death or CV event, and
1270 died or developed ESRD. In univariate analysis,
individuals with retinopathy were 1.28 times more likely
to develop the primary renal composite endpoint of
ESRD or death (95% CI 1.15 to 1.43), and nearly twice
as likely to progress to ESRD than those without retinop-
athy (HR 1.83; 95% CI 1.56 to 2.13). There was no dif-
ference between groups in the primary CV composite
endpoint, or its individual endpoint components of
death, myocardial infarction, stroke or congestive heart
failure (table 2). There were no interactions between
retinopathy and sex or treatment with darbepoetin alfa
and outcomes. Among patients with retinopathy, there
were no statistically signiﬁcant differences in event rates
for any outcome when patients were further subdivided
by a history of laser photocoagulation.
Table 3 shows the stepwise changes in HRs following
adjustment for baseline differences between patients
with and without retinopathy. After adjustment for
demographics, retinopathy continued to be independ-
ently associated with adverse renal outcomes. The add-
ition of the baseline level of proteinuria to the model
made the renal composite model non-signiﬁcant,
though retinopathy continued to be predictive of the
development of ESRD. Further correction for baseline
eGFR attenuated much of the remaining hazard asso-
ciated with retinopathy and correction for blood
Figure 1 Complications of
diabetes mellitus. †In this
category, only men were
included, N=1726.
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pressure rendered retinopathy non-signiﬁcant for the
prediction of adverse events. Additional correction for
baseline differences between groups further attenuated
the correlation between retinopathy and cardiorenal
outcomes. Among patients with retinopathy, there was
no difference in event rates between patients based on a
history of laser photocoagulation for advanced retinal
disease. There was also no difference in event rates
between patients with no retinopathy and those with a
history of laser therapy for advanced disease.
DISCUSSION
These analyses demonstrate that retinopathy is common
and present in approximately half of a group of patients
with type 2 diabetes mellitus, moderate anemia, and
moderate to severe CKD. In TREAT, nearly 30% of
patients had advanced diabetic retinopathy as assessed
by a history of laser photocoagulation, higher than the
15% found in the RIACE cohort,15 but still lower than
the prevalence in patients with type 1 diabetes.16 Similar
to prior cohorts of patients with type 2 diabetes,15 17 we
found that when present, retinopathy identiﬁed patients
who were younger had a longer known duration of dia-
betes, worse glycemic control, more insulin use, and a
higher prevalence of hypertension. Diabetes is a systemic
disease, and as expected from the baseline
characteristics, individuals with retinopathy also had
higher rates of all other microvascular complications
including not only nephropathy but also neuropathy.
Several studies have found diabetic retinopathy to be
associated with mortality and incident CV disease in
patients with type 2 diabetes mellitus.2–7 In a recent ana-
lysis of the ACCORD trial, Gerstein et al4 demonstrated a
positive relationship between baseline severity of retinop-
athy and incident CV events. The relationship persisted
after adjustment for prior CV disease, HbA1c, systolic
blood pressure, and several other baseline variables;
however, neither renal function nor proteinuria was
included in their model. Only a few of the prior studies
took proteinuria into account in their multivariable
models and none corrected for eGFR.5–7 Our data,
incorporating these factors, do not conﬁrm the prior
ﬁndings, and suggest that adjustment for renal complica-
tions would explain much of the contribution from ret-
inopathy in those prior studies.
Although retinopathy was associated with a higher
likelihood of the development of the renal composite
endpoint and ESRD in unadjusted analyses, once the
baseline eGFR, urine protein/creatinine ratio, blood
pressure, and diabetes severity were accounted for, this
was no longer the case. This ﬁnding was consistent with
the results of an analysis from the RENAAL trial, which
also showed that individuals with retinopathy had a
Table 3 Multivariable modeling
Renal composite ESRD
HR (95% CI) HR (95% CI)
Unadjusted 1.28 (1.15 to 1.43) 1.83 (1.56 to 2.13)
Model 1 adjusted for age, sex, and race 1.30 (1.16 to 1.45) 1.62 (1.38 to 1.90)
Model 2 model 1+proteinuria 1.07 (0.96 to 1.21) 1.23 (1.05 to 1.45)
Model 3 model 2+ eGFR 1.05 (0.94 to 1.18) 1.18 (1.01 to 1.38)
Model 4 model 3+SBP and history of HTN 1.06 (0.94 to 1.18) 1.16 (0.99 to 1.37)
Model 5 model 4+known duration of diabetes, HbA1c, and insulin use 1.00 (0.88 to 1.23) 1.09 (0.92 to 1.29)
Model 6 model 5+smoking status, CAD, atrial fibrillation, ACE/ARB use, aldosterone
inhibitor use, total cholesterol, CRP, and treatment with darbepoetin
1.06 (0.93 to 1.20) 1.12 (0.94 to 1.32)
ARB, angiotensin receptor blocker; CAD, coronary artery disease; CRP, C reactive protein; eGFR, estimated glomerular filtration rate;
HbA1c, glycosylated hemoglobin; HTN, hypertension; SBP, systolic blood pressure.
Table 2 Event rates (per 100 person-years) in TREAT among patients with and without retinopathy
Event rate* (95% CI)
Unadjusted HR (95% CI)No Retinopathy N=2143 Retinopathy N=1895
CV composite 13.4 (12.4 to 14.5) 13.9 (12.8 to 15.1) 1.04 (0.93 to 1.16)
Death from any cause 8.1 (7.4 to 8.9) 8.1 (7.3 to 8.9) 0.99 (0.87 to 1.14)
CV death 4.9 (4.3 to 5.5) 5.4 (4.7 to 6.1) 1.10 (0.92 to 1.31)
Myocardial infarction 2.6 (2.2 to 3.1) 2.8 (2.3 to 3.3) 1.07 (0.83 to 1.36)
Stroke 1.7 (1.3 to 2.1) 1.6 (1.3 to 2.0) 0.96 (0.70 to 1.32)
Congestive heart failure 4.6 (4.0 to 5.2) 5.0 (4.4 to 5.7) 1.10 (0.91 to 1.32)
Renal composite (ESRD or death) 12.2 (11.3 to 13.2) 15.6 (14.5 to 16.8) 1.28 (1.15 to 1.43)
ESRD 5.3 (4.7 to 6.0) 9.7 (8.8 to 10.7) 1.83 (1.56 to 2.13)
*Event rates are per 100 patient years.
CV, cardiovascular; ESRD,end-stage renal disease; TREAT, Trial to Reduce cardiovascular Events with Aranesp Therapy.
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similar risk of progressing to ESRD or death that was
mitigated by the addition of proteinuria and eGFR in
multivariate analysis.18 Neither retinopathy nor laser
photocoagulation as a marker of advanced disease was
independently associated with a higher risk of renal
morbidity or mortality in TREAT. Future studies such as
DIACORE,19 a prospective cohort study of 6000 patients
with type 2 diabetes mellitus for incident microvascular
and macrovascular complications with a focus on renal
events, should help to further elucidate the relationship
between retinopathy and the development of ESRD in
type 2 diabetes.
In a subset of patients who had cardiac biomarker ana-
lysis, we found that signiﬁcantly more patients with retin-
opathy had detectable troponin levels than those without
retinopathy, though there was no difference seen in
NT-proBNP. This ﬁnding is hypothesis generating, and
the increase in TnT in patients with retinopathy may be
related to changes in cardiac structure and function, as
Aguilar et al20 have shown that more severe diabetic retin-
opathy is associated with increased left ventricular mass,
and lower left ventricular ejection fraction. Alternatively,
elevations in cardiac biomarkers have also been shown to
increase in relation to proteinuria, and may reﬂect sys-
temic factors associated with CKD progression and a
shared progression of CV and renal disease.13
The strengths of this study include the large number
of participants and events and the masked endpoint
adjudication process. There were 668 patients who pro-
gressed to ESRD in TREAT over the 2.4 years of
follow-up. A limitation of this analysis is the presumably
mixed etiology of CKD in TREAT; however, 64% of
TREAT patients had proteinuria (>200 mg/g) and prior
work has shown that the presence of albuminuria is asso-
ciated with biopsy-proven diabetic glomerulosclerosis in
77% of cases.21 In addition, the presence of diabetic ret-
inopathy in patients with albuminuria strongly suggests
that diabetic glomerulopathy is the cause of albumin-
uria.21 22 We cannot make assumptions about the homo-
geneity of renal disease in TREAT. The investigator
report of retinopathy status and a history of laser
therapy, rather than the use of retinal photography, is
another limitation of this analysis. The discrimination of
the etiology of retinopathy is limited as well. However,
the physician report was internally consistent with trends
in other microvascular complications, and the 47%
prevalence was similar to the 49% prevalence reported
in the CRIC study of patients with type 2 diabetes melli-
tus and CKD that based the diagnosis on retinal photog-
raphy.23 24 The potential for residual confounding due
to an unmeasured covariate is also a limitation, though
we selected variables to best ﬁt a parsimonious model
that is reﬂective of our clinical judgment and the statis-
tical evidence. Because this is a selected population of
patients with type 2 diabetes mellitus who have moderate
to severe renal dysfunction and anemia, the results may
not be applicable to other populations such as those
with type 1 diabetes mellitus or less severe CKD.
In summary, retinopathy identiﬁed a group of patients
who were younger, yet had a longer known duration of dia-
betes with worse glycemic control and higher rates of
insulin use. Although it is common and the leading cause
of blindness in the developed world, the presence of retin-
opathy in patients with type 2 diabetes mellitus, moderate
to severe CKD, and anemia did not provide additional
prognostic information about CV or renal events after
taking into consideration baseline renal function/status.
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